Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Chronic kidney disease (CKD) is an established risk factor for cardiovascular morbidity and
mortality, as shown by common manifestations of left ventricular hypertrophy (LVH) and
arterial calcifications in CKD patients. Fibroblast growth factor-23(FGF-23) is a recently
identified phosphaturic hormone that has been reported to be associated with the development
of secondary hyperparathyroidism, cardiovascular morbidity, mortality, CKD progression.
While vitamin D is the mainstay therapy in CKD mineral bone disease (CKD-MBD), increased
FGF-23 levels have been reported with vitamin D administration. The purpose of this study was
to investigate the effect of calcium carbonate when used in conjunction with calcitriol on
FGF-23.